Cargando…
MiR-26a Enhances the Sensitivity of Gastric Cancer Cells to Cisplatin by Targeting NRAS and E2F2
BACKGROUND/AIMS: MiR-26a has been identified as a tumor suppressor in various tumors, but the relationship between miR-26a and the sensitivity of gastric cancer to chemotherapies has not been established. The present study was performed to investigate the effect of miR-26a on drug sensitivity in gas...
Autores principales: | Wen, Lan, Cheng, Fangzhi, Zhou, Yanyan, Yin, Chunhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632257/ https://www.ncbi.nlm.nih.gov/pubmed/26458859 http://dx.doi.org/10.4103/1319-3767.166206 |
Ejemplares similares
-
E2F1 promotes cancer cell sensitivity to cisplatin by regulating the cellular DNA damage response through miR-26b in esophageal squamous cell carcinoma
por: Zhang, Kun, et al.
Publicado: (2020) -
NRAS Contributes to Retinoblastoma Progression Through SNHG16/miR-183-5p/NRAS Regulatory Network
por: Sun, Guangli, et al.
Publicado: (2019) -
Overexpression of miR-26b decreases the cisplatin-resistance in laryngeal cancer by targeting ATF2
por: Tian, Linli, et al.
Publicado: (2017) -
Expression of miR-195 is associated with chemotherapy sensitivity of cisplatin and clinical prognosis in gastric cancer
por: Ye, Rui, et al.
Publicado: (2017) -
Loss of miR-143 and miR-145 in condyloma acuminatum promotes cellular proliferation and inhibits apoptosis by targeting NRAS
por: Liu, Xiaoyan, et al.
Publicado: (2018)